What ICMR study reveals about efficacy of Covishield against Delta strain

Covid recovered with one or two doses of vaccine have higher protection against Delta variant in comparison to those given either one or two doses of Covishield, a study stated.

Covid vaccination
A villager receives a dose of Covishield vaccine during a door-to-door vaccination and testing drive at Uttar Batora Island in Howrah district in West Bengal (Photo: Reuters)
Press Trust of India New Delhi
2 min read Last Updated : Jul 04 2021 | 5:49 PM IST

Breakthrough cases and COVID-19 recovered individuals with one or two doses of vaccine have relatively higher protection against Delta variant in comparison to those administered either one or two doses of Covishield, a study stated.

Prior vaccination results in less severe disease against subsequent infection provide evidence that both humoral and cellular immune response play an important role in protection, according to the study which is yet to be peer-reviewed and was posted on bioRxiv preprint server on Friday.

The study 'Neutralisation of Delta Variant with Sera of Covishield vaccines and COVID-19 Recovered Vaccinated Individuals' has been done by scientists from the Indian Council of Medical Research (ICMR), National Institute of Virology, Pune, and Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College, Pune.

The recent emergence of B.1.617 lineage has created grave public health problem in India.

The lineage further mutated to generate sub-lineages B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3. Apparently, the Delta variant has slowly dominated the other variants. With this, the World Health Organisation has described this sub-lineage as variant of concern, the study stated.

"The high transmissibility associated with Delta variant led to second wave of the pandemic in India which affected millions of people. Besides this, variant of concerns have been reported to show lower neutralisation to several approved vaccines. This has led to breakthrough infections after completion of vaccination regimen," it said.

There is limited information available on the duration of protective immune response post-infection, vaccination or breakthrough infection with SARS-CoV-2.

The study evaluated immune response in sera of the Covishield vaccinated individuals belonging to categories-- one dose vaccinated, two doses vaccinated, COVID-19 recovered plus one dose vaccinated, COVID-19 recovered plus two doses vaccinated and breakthrough COVID-19 cases.

"The findings of the study demonstrated that the breakthrough cases and COVID-19 recovered individuals with one or two dose of vaccine had relatively higher protection against Delta variant in comparison to the participants who were administered either one or two doses of Covishield.

"Prior vaccination results in less severe disease against subsequent infection provide evidence that both humoral and cellular immune response play an important role in protection," the study added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Jul 04 2021 | 5:41 PM IST

Next Story